ConductScience.org, home

Paper35889596

Graphene Oxide Nanoplatforms to Enhance Cisplatin-Based Drug Delivery in Anticancer Therapy.

Giusto E and 9 others. Nanomaterials (Basel), 2022. Cited by 28 papers, by iCite.

Cite this record

ConductScience Library. Graphene Oxide Nanoplatforms to Enhance Cisplatin-Based Drug Delivery in Anticancer Therapy. Papers, record 35889596. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/35889596

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Graphene Oxide Nanoplatforms to Enhance Cisplatin-Based Drug Delivery in Anticancer Therapy.
PubMed
Journal
Nanomaterials (Basel)
PubMed
Year
2022
PubMed
Publication types
Journal Article
PubMed
Citations, by iCite
28
iCite
Relative citation ratio, by iCite
2.55
iCite
Revised in PubMed
2022-07-31
PubMed

Authors10

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

Source PubMed

Download CSV of authors

Topics0

NLM's MeSH indexing of the paper, its major topics first.

None in this release.

Grants1

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

Grant, as the record writes itAgencyCountryNIH projectStated by
952063European CommissionPubMed

Source PubMed

Download CSV of grants

References49

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
132290213Glioblastoma: Pathogenesis and Current Status of Chemotherapy and Other Novel Treatments.Cancers (Basel)2020https://conductscience.org/library/papers/32290213PubMed
230640441Toward Multi-Targeted Platinum and Ruthenium Drugs-A New Paradigm in Cancer Drug Treatment Regimens?Chem Rev2019https://conductscience.org/library/papers/30640441PubMed
334226520Platinum drugs and taxanes: can we overcome resistance?Cell Death Discov2021https://conductscience.org/library/papers/34226520PubMed
419617894Inhibition of MMP-3 activity and invasion of the MDA-MB-231 human invasive breast carcinoma cell line by bioflavonoids.Acta Pharmacol Sin2009https://conductscience.org/library/papers/19617894PubMed
530405765
Hesperidin exhibits in vitro and in vivo antitumor effects in human osteosarcoma MG-63 cells and xenograft mice models via inhibition of cell migration and invasion, cell cycle arrest and induction of mitochondrial-mediated apoptosis.
Oncol Lett2018https://conductscience.org/library/papers/30405765PubMed
632343992Application of star poly(ethylene glycol) derivatives in drug delivery and controlled release.J Control Release2020https://conductscience.org/library/papers/32343992PubMed
724656608One-step reduction and PEGylation of graphene oxide for photothermally controlled drug delivery.Biomaterials2014https://conductscience.org/library/papers/24656608PubMed
834399040Global patterns of breast cancer incidence and mortality: A population-based cancer registry data analysis from 2000 to 2020.Cancer Commun (Lond)2021https://conductscience.org/library/papers/34399040PubMed
931847897Nanotechnology in cancer diagnosis: progress, challenges and opportunities.J Hematol Oncol2019https://conductscience.org/library/papers/31847897PubMed
1026082884Nanotechnology for cancer treatment.Nanotechnol Rev2015https://conductscience.org/library/papers/26082884PubMed
1127315174Bio-inspired cisplatin nanocarriers for osteosarcoma treatment.Biomater Sci2016https://conductscience.org/library/papers/27315174PubMed
1230918918Bone as a Preferential Site for Metastasis.JBMR Plus2019https://conductscience.org/library/papers/30918918PubMed
1330405759Progress in the chemotherapeutic treatment of osteosarcoma.Oncol Lett2018https://conductscience.org/library/papers/30405759PubMed
1429309917Breast cancer bone metastases: pathogenesis and therapeutic targets.Int J Biochem Cell Biol2018https://conductscience.org/library/papers/29309917PubMed
1526855010Improved In Vitro and In Vivo Biocompatibility of Graphene Oxide through Surface Modification: Poly(Acrylic Acid)-Functionalization is Superior to PEGylation.ACS Nano2016https://conductscience.org/library/papers/26855010PubMed
1616640401Functionalized single graphene sheets derived from splitting graphite oxide.J Phys Chem B2006https://conductscience.org/library/papers/16640401PubMed
1727133053Improved tumor targeting and antitumor activity of camptothecin loaded solid lipid nanoparticles by preinjection of blank solid lipid nanoparticles.Biomed Pharmacother2016https://conductscience.org/library/papers/27133053PubMed
1819778015Polyvalent oligonucleotide gold nanoparticle conjugates as delivery vehicles for platinum(IV) warheads.J Am Chem Soc2009https://conductscience.org/library/papers/19778015PubMed
1930833579Assessing metastatic potential of breast cancer cells based on EGFR dynamics.Sci Rep2019https://conductscience.org/library/papers/30833579PubMed
2023402618Uniform ultrasmall graphene oxide nanosheets with low cytotoxicity and high cellular uptake.ACS Appl Mater Interfaces2013https://conductscience.org/library/papers/23402618PubMed

See all 49 referencesDownload CSV of references

Cited by17

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 28 citations.

PMIDTitleJournalYearIn PapersSource
40861299Synergistic chemotherapy and phototherapy co-delivery nanoparticle preparation and anti-triple negative breast cancer study.RSC Adv2025https://conductscience.org/library/papers/40861299PubMed
40826206High-throughput profiling of chemical-induced gene expression across 93,644 perturbations.Nat Methods2025https://conductscience.org/library/papers/40826206PubMed
40558899Material-Driven Therapeutics: Functional Nanomaterial Design Paradigms Revolutionizing Osteosarcoma Treatment.J Funct Biomater2025https://conductscience.org/library/papers/40558899PubMed
40095051Oxidative phosphorylation and breast cancer progression: insights into PGC-1α's role in mitochondrial function.Naunyn Schmiedebergs Arch Pharmacol2025https://conductscience.org/library/papers/40095051PubMed
39962959Stimuli-responsive Graphene-polysaccharide Nanocomposites for Drug Delivery and Tissue Engineering.Curr Org Synth2025https://conductscience.org/library/papers/39962959PubMed
39850060Combined Graphene Oxide with 2-Methoxyestradiol for Effective Anticancer Therapy in-vitro Model.Int J Nanomedicine2025https://conductscience.org/library/papers/39850060PubMed
39742149Orchestrating cancer therapy: Recent advances in nanoplatforms harmonize immunotherapy with multifaceted treatments.Mater Today Bio2025https://conductscience.org/library/papers/39742149PubMed
38931957Development of Graphene Oxide-Based Anticancer Drug Combination Functionalized with Folic Acid as Nanocarrier for Targeted Delivery of Methotrexate.Pharmaceutics2024https://conductscience.org/library/papers/38931957PubMed
38903671A minireview on the utilization of petroleum coke as a precursor for carbon-based nanomaterials (CNMs): perspectives and potential applications.RSC Adv2024https://conductscience.org/library/papers/38903671PubMed
38817436Graphene oxide and oxidized carbon nanodiscs as biomedical scaffolds for the targeted delivery of quercetin to cancer cells.Nanoscale Adv2024https://conductscience.org/library/papers/38817436PubMed
387702722D and 3D anticancer properties of C2-functionalised glucosamine-Pt (IV) prodrugs based on cisplatin scaffold.Front Chem2024https://conductscience.org/library/papers/38770272PubMed
38112935An updated landscape on nanotechnology-based drug delivery, immunotherapy, vaccinations, imaging, and biomarker detections for cancers: recent trends and future directions with clinical success.Discov Nano2023https://conductscience.org/library/papers/38112935PubMed
37534260Optical properties of nanostructured antiviral and anticancer drugs.RSC Adv2023https://conductscience.org/library/papers/37534260PubMed
37242787Carbon Nanomaterials (CNMs) in Cancer Therapy: A Database of CNM-Based Nanocarrier Systems.Pharmaceutics2023https://conductscience.org/library/papers/37242787PubMed
37242042Advanced Nanomaterials in Biomedical Application.Nanomaterials (Basel)2023https://conductscience.org/library/papers/37242042PubMed
37177003Cytotoxicity of Carbon Nanotubes, Graphene, Fullerenes, and Dots.Nanomaterials (Basel)2023https://conductscience.org/library/papers/37177003PubMed
37149615Therapeutic applications of nanobiotechnology.J Nanobiotechnology2023https://conductscience.org/library/papers/37149615PubMed

Download CSV of cited by

Genes1

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn Genes
ALB213PubTator's text mininghttps://conductscience.org/library/genes/213

Source NCBI Gene

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Trials
  • Comments and corrections
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/35889596

GET https://conductscience.org/api/papers/v1/35889596/references?page=2